CH50 Assay

CH50 kit (100 determinations)Order button

European Union Price €395,-

Inquire for a quotation if you are located outside the European Union.



Complement hemolytic activity is a functional test of the classical and alternative pathway of complement in plasma or serum. The classical pathway method (CH50) is based on lysis of sensibilized sheep erythrocytes in the presence of Ca++ and Mg++. This method is suited to evaluate the haemocompatibility of biomaterials and medical devices according to the international standard ISO 10993-4:2002 after blood, plasma, or serum contact with biomaterials and to assess the effects of pharmaceuticals on inhibition or consumption of complement components.



Measuring classical pathway complement activity. This kit is intended for laboratory research use only and is not for use in diagnostic or therapeutic procedures. The analysis should be performed by trained laboratory professionals.



An erythrocyte suspension is incubated for 30 minutes with serial diluted serum or plasma at 37 ºC. After incubation samples are centrifuged to obtain supernatant, containing free hemoglobin. The hemoglobin concentration is measured by means of a spectrophotometer. Positive reference is total lysis induced by lysis fluid, negative reference is obtained after incubation with buffer. The kit is designed to determine hemolytic activity of small samples (50 μL or less). And can be performed in a 96 well microtiter plate.


Storage and Stability

Product is stable at 4 °C for at least one month.


Download kit insert



Misra SK, Chang HH, Mukherjee P, Tiwari S, Ohoka A, Pan D. Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities. Sci Rep. 2015 Oct 14;5:14986.


Mukherjee P, Misra SK, Gryka MC, Chang HH, Tiwari S, Wilson WL, Scott JW, Bhargava R, Pan D. Tunable Luminescent Carbon Nanospheres with Well-Defined Nanoscale Chemistry for Synchronized Imaging and Therapy. Small. 2015 Sep;11(36):4691-703.


Luo J, Lindstrom J. Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis. J Immunol. 2014 Nov 15;193(10):5044-55.